^
Association details:
| Biomarker: | PDGFRB fusion |
|---|---|
| Cancer: | Childhood B Acute Lymphoblastic Leukemia |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
Published date:
09/11/2014
Excerpt:
We examined the functional effects of fusion proteins and the efficacy of tyrosine kinase inhibitors in mouse pre-B cells and xenografts of human Ph-like ALL....Cell lines and human leukemic cells expressing ABL1, ABL2, CSF1R, and PDGFRB fusions were sensitive in vitro to dasatinib, EPOR and JAK2 rearrangements were sensitive to ruxolitinib, and the ETV6–NTRK3 fusion was sensitive to crizotinib.
DOI:
10.1056/NEJMoa1403088
